Graph Therapeutics develops precision therapeutics for inflammatory and immune-mediated diseases by combining perturbation modelling of complex live patient samples, functional and multi-omics profiling, and advanced machine learning in a proprietary "lab-in-the-loop" AI platform. The company uses insights derived directly from patient tissue to identify disease mechanisms, novel therapeutic targets, and biomarkers to inform differentiated therapy development. Graph has validated and de-risked its platform with clinically relevant biological models and is advancing an internal pipeline of precision drug candidates across multiple indications. The maturity of the platform also creates opportunities for strategic partnerships and out-licensing to extend the technology beyond its internal programs. Financially, Graph has raised more than $10 million to date, comprising equity investments and non-dilutive grant funding.

Total raised

$8M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2026